Literature DB >> 11588103

The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists.

J Pil1, J Tytgat.   

Abstract

1. To investigate the effect of the hydrophilic Asn amino acid at position 230 of the human mu-opioid receptor (hMOR230) on the potency of various agonists, we mutated this residue to Thr and Leu (hMORN230T and hMORN230L respectively). 2. Taking advantage of the functional coupling of the opioid receptor with the heteromultimeric G-protein-coupled inwardly rectifying K(+) (GIRK1/GIRK2) channel, either the wild type hMOR or one of the mutated receptors (hMORN230L or hMORN230T) were functionally coexpressed with GIRK1/GIRK2 channels and a regulator of G-protein signalling (RGS4) in Xenopus laevis oocytes. 3. The two-microelectrode voltage clamp technique was used to measure the opioid receptor-activated GIRK1/GIRK2 channel responses. The potency of [D-Ala(2),N-MePhe(4),Gly(5)-ol]-enkephalin (DAMGO), remained unaffected as measured via hMORN230T and hMORN230L, while the potency of fentanyl and morphine significantly increased via these mutated receptors. 4. Our results are indicative for the existence of hydrophobic interactions between a methyl-group of the side chain of Thr or Leu on the one hand and the piperidine-ring of fentanyl and the hexene-ring of morphine on the other. The mutations also had no influence on the potency of morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). 5. We conclude that the hydrophilic side chain of Asn in position 230 is not involved in the formation of a H-bond with the aliphatic alcohol of morphine and that an enhancement of the potency of morphine and fentanyl can be explained by mutating this residue towards more hydrophobic amino acids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588103      PMCID: PMC1572970          DOI: 10.1038/sj.bjp.0704263

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.

Authors:  M Filizola; L Laakkonen; G H Loew
Journal:  Protein Eng       Date:  1999-11

2.  Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.

Authors:  E R Liman; J Tytgat; P Hess
Journal:  Neuron       Date:  1992-11       Impact factor: 17.173

3.  RGS proteins reconstitute the rapid gating kinetics of gbetagamma-activated inwardly rectifying K+ channels.

Authors:  C A Doupnik; N Davidson; H A Lester; P Kofuji
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

Authors:  C E Spivak; C L Beglan; B K Seidleck; L D Hirshbein; C J Blaschak; G R Uhl; C K Surratt
Journal:  Mol Pharmacol       Date:  1997-12       Impact factor: 4.436

5.  Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

Authors:  C Chen; J Yin; J K Riel; R L DesJarlais; L F Raveglia; J Zhu; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

6.  Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study.

Authors:  A Mansour; L P Taylor; J L Fine; R C Thompson; M T Hoversten; H I Mosberg; S J Watson; H Akil
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

7.  A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.

Authors:  M Minami; T Nakagawa; T Seki; T Onogi; Y Aoki; Y Katao; S Katsumata; M Satoh
Journal:  Mol Pharmacol       Date:  1996-11       Impact factor: 4.436

8.  The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.

Authors:  B L Kieffer; K Befort; C Gaveriaux-Ruff; C G Hirth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors.

Authors:  T Seki; M Minami; T Nakagawa; Y Ienaga; A Morisada; M Satoh
Journal:  Eur J Pharmacol       Date:  1998-06-05       Impact factor: 4.432

10.  Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.

Authors:  I D Pogozheva; A L Lomize; H I Mosberg
Journal:  Biophys J       Date:  1998-08       Impact factor: 4.033

View more
  1 in total

Review 1.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.